Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $114.8 million.

  • Viking Therapeutics' Shares Outstanding rose 288.56% to $114.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $114.8 million, marking a year-over-year increase of 288.56%. This contributed to the annual value of $114.8 million for FY2025, which is 288.56% up from last year.
  • Per Viking Therapeutics' latest filing, its Shares Outstanding stood at $114.8 million for Q4 2025, which was up 288.56% from $112.4 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Shares Outstanding registered a high of $114.8 million during Q4 2025, and its lowest value of $76.7 million during Q2 2022.
  • Its 5-year average for Shares Outstanding is $94.8 million, with a median of $100.0 million in 2023.
  • In the last 5 years, Viking Therapeutics' Shares Outstanding plummeted by 197.66% in 2022 and then surged by 3896.89% in 2024.
  • Over the past 5 years, Viking Therapeutics' Shares Outstanding (Quarter) stood at $78.2 million in 2021, then increased by 0.01% to $78.3 million in 2022, then rose by 27.93% to $100.1 million in 2023, then rose by 11.45% to $111.6 million in 2024, then grew by 2.89% to $114.8 million in 2025.
  • Its Shares Outstanding stands at $114.8 million for Q4 2025, versus $112.4 million for Q3 2025 and $112.3 million for Q2 2025.